Table 1.
Sample Characteristics
| Randomized Samplea (N = 43) |
Completers Sampleb (N = 27) |
|||
|---|---|---|---|---|
| Condition | Placebo (n = 21) |
70 mg LDXc (n = 22) |
Placebo (n = 15) |
70 mg LDXc (n = 12) |
| Demographic | ||||
| Aged | 46.4 (10) | 45.1 (5.9) | 46.7 (7.7) | 43.9 (7.7) |
| % Femalee | 18.2 (4) | 21.1 (4) | 20.0 (3) | 16.3 (2) |
| Educationd | 12.9 (1.5) | 12.8 (1.7) | 13 (1.7) | 13.3 (1.7) |
| %Racee | ||||
| Black | 63.2 (12) | 63.6 (14) | 60.0 (9) | 75.0 (9) |
| White | 15.8 (3) | 36.4 (8) | 13.3 (2) | 25.0 (3) |
| Other | 21.1 (4) | 0 (0) | 26.7 (4) | 0 (0) |
| % Marriede | 4.5 (1) | 5.3 (1) | 6.67 (1) | 0 (0) |
| % Employede | 22.7 (5) | 21.1 (4) | 33.3 (5) | 25.0 (3) |
| Drug Use | ||||
| %Intake Cocainee | 68.2 (15) | 89.5 (17) | 86.7 (13) | 84.1 (12) |
| Cocaine Use (30 days) d |
16.1 (9.1) | 12.7 (6.5) | 13.6 (6.4) | 17.9 (6.4) |
| Nicotine Use (30 days) d |
26.5 (7.9) | 28.5 (11.4) | 26.8 (0) | 30.0 (0) |
| Marijuana Use (30 days) d |
9.0 (10.0) | 11.4 (11.9) | 11.3 (12.1) | 12.4 (12.1) |
| Cocaine (Yrs.) d | 7.1 (9.2) | 13.5 (7.7) | 16.5 (9.2) | 6.4 (9.2) |
| Alcohol (Yrs.) d | 5.4 (9.7) | 9.1 (10.3) | 11 (9.2) | 5.7 (9.2) |
| Marijuana (Yrs.) d | 7 (10.2) | 8.9 (10.6) | 7.6 (10.9) | 9 (10.9) |
| ASI Scores | ||||
| Medicald | 0.27 (0.36) | 0.15 (0.22) | 0.17 (0.39) | 0.33 (0.39) |
| Employmentd | 0.72 (0.3) | 0.78 (0.3) | 0.78 (0.37) | 0.65 (0.37) |
| Alcohold | 0.10 (0.15) | 0.19 (0.15) | 0.24 (0.13) | 0.08 (0.13) |
| Drugd | 0.22 (0.08) | 0.21 (0.06) | 0.22 (0.06) | 0.23 (0.06) |
| Legald | 0.06 (0.1) | 0.09 (0.17) | 0.03 (0.12) | 0.07 (0.12) |
| Family/Sociald | 0.18 (0.16) | 0.17 (0.12) | 0.13 (0.16) | 0.17 (0.16) |
| Psychiatricd | 0.11 (0.16) | 0.17 (0.18) | 0.11 (0.12) | 0.09 (0.12) |
Note. Comparability of study groups across baseline demographic and substance-use variables was evaluated using t-tests for continuous variables and chi-square tests for categorical variables. No significant differences were observed among conditions on any variable.
a
Randomized Sample = 43 subjects who were randomized to treatment.
b
Completers Sample = 27 subjects finishing the 14-week trial.
c
LDX = Lisdexamfetamine.
d
Mean and standard deviation.
e
Percentage and n.